Table 2.
Subjective symptom or condition improvement after treatment as assessed with the VAS.
| Studied parameters | Group A | Group B | ||
|---|---|---|---|---|
| After RCE | After placebo | After placebo | After RCE | |
| Scalp hair (better texture, less fragility, and overall condition) | 7.3 ± 16.6†
[0, 0] |
4.2 ± 13.9 [0, 0] |
0.2 ± 0.9 [0, 0] |
6.3 ± 13.9* [0, 0] |
|
| ||||
| Body hair (less growth) | 6.4 ± 16.5 [0, 0] |
2.6 ± 10.9* [0, 0] |
1.0 ± 3.4 [0, 0] |
2.2 ± 6.2 [0, 0] |
|
| ||||
| Skin condition (better texture, more moisture, and better overall condition) | 18.6 ± 20.5†
[15, 32] |
6.2 ± 16.2* [0, 0] |
5.0 ± 11.0 [0, 5] |
17.7 ± 21.2∗†
[5, 35.0] |
|
| ||||
| Ocular complaint (dryness and burning) | 7.8 ± 18.0†
[0, 7] |
5.3 ± 15.1 [0, 0] |
2.2 ± 9.5 [0, 0] |
6.0 ± 13.7 [0, 1.3] |
|
| ||||
| Oral mucosa complaint (dryness and burning) | 3.9 ± 14.0 [0, 0] |
3.3 ± 13.0 [0, 0] |
1.8 ± 5.2 [0, 0] |
2.8 ± 9.7 [0, 0] |
|
| ||||
| Nasal mucosa complaint (dryness and fissuring) | 4.2 ± 15.3 [0, 0] |
2.6 ± 9.1 [0, 0] |
1.6 ± 5.3 [0, 0] |
6.2 ± 16.1* [0, 1.3] |
|
| ||||
| Nails condition (change in thickness and stability) | 5.6 ± 16.2 [0, 0] |
6.2 ± 16.7 [0, 0] |
3.3 ± 10.0 [0, 1.3] |
10.8 ± 19.3* [0, 11.3] |
|
| ||||
| Digestive complaints (diarrhea and constipation) | 6.0 ± 16.1†
[0, 0] |
14.4 ± 19.4* [0, 32.0] |
19.5 ± 26.0 [6, 31.3] |
11.9 ± 26.4* [0, 10.8] |
|
| ||||
| Libido | 18.0 ± 16.7†
[17, 30] |
4.9 ± 14.3* [0, 0] |
5.0 ± 12.4 [0, 1.3] |
17.8 ± 20.9∗†
[10, 30] |
|
| ||||
| Urinary complaint (incontinence and dysuria) | 5.2 ± 18.1 [0, 0] |
5.4 ± 17.3 [0, 0] |
3.0 ± 13.7 [0, 0] |
4.7 ± 15.0 [0, 0] |
|
| ||||
| Mood complaint | 68.5 ± 33.6†
[80, 48] |
15.0 ± 25.2* [0, 25.3] |
7.7 ± 19.2 [0, 0.8] |
65.8 ± 37.8∗†
[78.5, 70.5] |
|
| ||||
| Sleeping complaint | 73.5 ± 33.4†
[90, 45] |
16.2 ± 25.7* [0, 25] |
9.8 ± 23.0 [0, 7] |
70.6 ± 3.5∗†
[81.5, 62.2] |
|
| ||||
| Tiredness | 61.7 ± 45.8†
[96, 100] |
16.1 ± 24.5* [0, 26.3] |
8.3 ± 22.7 [0, 0] |
56.1 ± 47.7∗†
[92.0, 100] |
|
| ||||
| Overall satisfaction with treatment | 87.3 ± 26.6†
[100, 12.5] |
29.8 ± 31.4* [30, 50] |
14.7 ± 26.8 [0, 19] |
81.7 ± 26.8∗†
[100, 43.7] |
Values are expressed as percent improvement and presented as mean ± standard deviations [median, interquartile range]; *P < 0.05 when comparing phases in same group using Wilcoxon rank test; † P < 0.05 as compared to placebo phase of the contrary group using the Mann-Whitney test.